Posted by Michael Wonder on 23 Jan 2023
ICER publishes final evidence report on fezolinetant for vasomotor symptoms associated with menopause
23 January 2023 - Independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit for fezolinetant when compared to no pharmacological treatment.
The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of fezolinetant (Astellas) for moderate to severe vasomotor symptoms associated with menopause.
